GlassScriptPhysician profile
William M Suh
NPI 1740200351
$62,127.29
in general payments reported to CMS, 2019-2025
36 companies · $4,952 in 2025
The $4,952 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $37K · 2021: $1,316 · 2022: $283 · 2023: $1,363 · 2024: $3,104 · 2025: $4,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Consulting Fee: $4,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.83 |
| Consulting Fee | $4,687.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $56,606.64 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $945.67 | 2019-2025 | Xience Skypoint, Pressurewire, Coroflow |
| Abiomed | $602.16 | 2019-2025 | Impella |
| Shockwave Medical, INC | $541.41 | 2019-2020 | |
| Amgen INC. | $467.97 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $405.01 | 2025 | Symplicity G3, Onyx Frontier, Abre |
| Amarin Pharma, INC. | $353.99 | 2020-2021 | |
| Boston Scientific Corporation | $274.53 | 2019-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $272.65 | 2020-2025 | |
| Janssen Biotech, INC. | $188.41 | 2023-2024 | Stelara, Erleada, Akeega |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.96 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $130.50 | 2023-2025 | Eliquis, Camzyos |
| Acist Medical Systems, INC. | $129.12 | 2019-2023 | |
| Pfizer INC. | $110.98 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $106.46 | 2022-2025 | Verquvo, Capvaxive |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $93.88 | 2023-2025 | |
| Scpharmaceuticals INC. | $93.61 | 2025 | |
| Biosense Webster, INC. | $88.38 | 2025 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $77.02 | 2024-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.25 | 2023-2025 | Jardiance |
| Venclose INC. | $54.66 | 2020 | |
| Cleerly, INC. | $47.89 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Philips North America LLC | $47.10 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Janssen Pharmaceuticals, INC | $32.88 | 2021 | |
| Redhill Biopharma INC. | $28.05 | 2023 | Talicia |
| Irhythm Technologies, INC. | $27.32 | 2023 | Zio Xt Patch |
| Novo Nordisk INC | $23.40 | 2025 | Wegovy |
| Avanos Medical | $22.49 | 2023 | On-Q* Pump and Accessories |
| Exact Sciences Corporation | $20.60 | 2024 | Cologuard Collection Kit |
| Zoll Circulation INC | $19.57 | 2022 | |
| Aspira Women'S Health INC | $18.12 | 2023 | Ova1 |
| Abbvie INC. | $17.58 | 2024 | |
| Siemens Medical Solutions USA, INC. | $15.15 | 2024 | Atellica Ch 930 Analyzer |
| Bard Peripheral Vascular, INC. | $14.56 | 2020 | |
| Glaxosmithkline, LLC. | $14.32 | 2025 | Arexvy, Shingrix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.